id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-313208-nfu8rdvh	Muccioli, Lorenzo	Subcortical myoclonus in COVID‐19: comprehensive evaluation of a patient	2020-08-07		.txt	text/plain	875	65	45	Cerebrospinal fluid (CSF) analysis, performed eight days after myoclonus onset, demonstrated 5 leukocytes/μL, elevated protein levels (75 mg/dL) and CSF/serum albumin ratio (13.1), and negative SARS-CoV-2 RT-PCR. Myoclonus onset timing and clinical course were also not consistent with an adverse drug reaction, a mechanism suggested in the form of serotonin syndrome in two patients treated with lopinavir/ritonavir. 2, Agitation and myoclonus were preceded by severe cytokine release syndrome, a distinctive feature of COVID-19. Interestingly, cytokine-mediated neuroinflammation induced by SARS-CoV-2 has been implicated in steroid-responsive COVID-19-associated encephalopathy. 5 In addition to marked agitation in our patient, previous reports also had clinical/instrumental findings suggestive of encephalopathy, including dysexecutive syndrome, delirium, somnolence, EEG slowing, elevated inflammatory markers, variable responses to immunotherapies and a benign clinical course, 1-4 further suggesting an immune-mediated/inflammatory pathogenesis. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir Cytokine release syndrome in severe COVID-19	./cache/cord-313208-nfu8rdvh.txt	./txt/cord-313208-nfu8rdvh.txt